Twist Bioscience Corp
TWSTNasdaq
$93.85
↑ +2.9%Jul 17 close · end-of-day
Price
1Y↑ +155.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.8B
Enterprise Value
$5.6B
P/E
—
P/S
14.1
P/B
12.7
EV/EBITDA
—
PEG
—
FCF Yield
-1.6%
Dividend Yield
—
Revenue (TTM)
$409.5M
Net Income (TTM)
-$81.3M
Free Cash Flow (TTM)
-$95.0M
Gross Margin
—
Operating Margin
-33.9%
Net Margin
-19.9%
ROE
-17.9%
ROIC
-38.7%
Debt / Equity
—
Net Cash
$171.7M
Return 1Y
+161.8%
Company profile
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
- CEO
- Emily M. Leproust
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 990
- Headquarters
- California
- Website
- twistbioscience.com
Earnings
TWST Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$110.7M↑ +19.3%
Diluted EPS-$0.71↑ +7.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $90.1M | $132.3M | $203.6M | $245.1M | $313.0M | $376.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$140.1M | -$152.7M | -$234.8M | -$217.2M | -$220.8M | -$136.3M |
| Net income | -$139.9M | -$152.1M | -$217.9M | -$204.6M | -$208.7M | -$77.7M |
| Diluted EPS | -$3.57 | -$3.15 | -$4.04 | -$3.60 | -$3.60 | -$1.30 |
| Operating cash flow | -$142.3M | -$112.2M | -$124.4M | -$142.5M | -$64.1M | -$47.6M |
| Free cash flow | -$152.1M | -$139.3M | -$226.2M | -$170.3M | -$69.2M | -$75.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -155.5% | -115.4% | -115.3% | -88.6% | -70.6% | -36.2% |
| Net margin | -155.3% | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81.5M | $84.7M | $88.7M | $92.8M | $96.1M | $99.0M | $103.7M | $110.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$88.9M | -$36.0M | -$34.6M | -$41.6M | -$30.1M | -$29.9M | -$32.9M | -$45.9M |
| Net income | -$85.6M | -$34.7M | -$31.6M | -$39.3M | $20.4M | -$27.1M | -$30.5M | -$44.0M |
| Diluted EPS | -$1.47 | -$0.59 | -$0.53 | -$0.66 | $0.33 | -$0.44 | -$0.50 | -$0.71 |
| Operating cash flow | -$6.4M | -$15.3M | -$21.4M | -$13.0M | -$1.4M | -$11.8M | -$24.8M | -$17.6M |
| Free cash flow | -$7.3M | -$17.3M | -$23.7M | -$17.1M | -$10.6M | -$24.2M | -$34.8M | -$25.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -109.2% | -42.5% | -39.1% | -44.8% | -31.4% | -30.2% | -31.7% | -41.4% |
| Net margin | -105.0% | -40.9% | -35.6% | -42.4% | 21.2% | -27.4% | -29.4% | -39.8% |
Company news
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.